Department of Oncology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China (mainland).
Department of Thoracic and Cardiovascular Surgery, Second Xiangya Hospital of Central South University, Changsha, Hunan, China (mainland).
Med Sci Monit. 2020 Jan 23;26:e919789. doi: 10.12659/MSM.919789.
BACKGROUND Primary clear cell carcinoma of the liver (PCCCL) is an infrequent variant of primary hepatocellular carcinoma (HCC), we retrospectively performed a large population-based cohort study to elucidate the relationships between demographic, carcinoma- and therapy-specific variables and overall survival (OS). MATERIAL AND METHODS The Surveillance, Epidemiology and End Results (SEER) database was queried to extract data on 419 patients with pathologically confirmed PCCCL from 1988 to 2015. A nomogram with good accuracy was formulated to predict long-term survival of PCCCL patients. RESULTS The OS for PCCCL patients was 25.6 months (95% confidence interval [CI]: 22.2-29 months), the overall 1-year, 3-year, and 5-year survival rates were 59.5%, 39.3%, and 29.9%, respectively. Log-rank analysis revealed that there was no statistically significant discrepancy in clinical outcome between PCCCL and common-type HCC after propensity-matched analysis. Multivariate Cox analysis confirmed that larger lesions (>96 mm), distant metastases and elevated alpha-fetoprotein (AFP) levels were independent prognostic factors for undesirable outcome. Conversely, surgery was an independent protective factor (hazard ratio [HR]=0.23, 95% CI 0.17-0.31), which significantly boosted OS by virtually 35 months (47.3 months versus 12.7 months, P<0.001). Radiotherapy or chemotherapy was not associated with OS for PCCCL patients (both P>0.05). The nomogram incorporated 4 independent prognostic factors and its concordance index for predicting survival was 0.761. CONCLUSIONS The prognosis of PCCCL resembled that of common-type HCC. Larger lesions, distant metastases, and enhanced AFP levels were associated with unsatisfactory prognosis. Surgery fulfill favorable prognosis while radiotherapy or chemotherapy exerted no significant effects on survival.
原发性肝透明细胞癌(PCCCL)是原发性肝细胞癌(HCC)的一种罕见亚型,我们回顾性地进行了一项大型基于人群的队列研究,以阐明人口统计学、癌和治疗特异性变量与总生存期(OS)之间的关系。
从 1988 年到 2015 年,我们通过监测、流行病学和最终结果(SEER)数据库查询提取了 419 例经病理证实的 PCCCL 患者的数据。制定了一个具有良好准确性的列线图来预测 PCCCL 患者的长期生存。
PCCCL 患者的 OS 为 25.6 个月(95%置信区间[CI]:22.2-29 个月),总 1 年、3 年和 5 年生存率分别为 59.5%、39.3%和 29.9%。对数秩分析显示,在倾向匹配分析后,PCCCL 和常见型 HCC 的临床结局无统计学差异。多变量 Cox 分析证实,较大的病变(>96mm)、远处转移和 AFP 水平升高是不良预后的独立预测因素。相反,手术是独立的保护因素(风险比[HR]=0.23,95%CI 0.17-0.31),几乎将 OS 提高了 35 个月(47.3 个月比 12.7 个月,P<0.001)。放疗或化疗与 PCCCL 患者的 OS 无关(均 P>0.05)。该列线图纳入了 4 个独立的预后因素,其预测生存率的一致性指数为 0.761。
PCCCL 的预后与常见型 HCC 相似。较大的病变、远处转移和 AFP 水平升高与预后不良相关。手术可带来良好的预后,而放疗或化疗对生存无显著影响。